Anteotech Ltd · ASX:ADO
Anteotech — Investor Presentation (September 2021)
21 slides from Anteotech's investor presentation, Sep 23, 2021
Slide 1: ASX Announcement: InvestorStream Interview - Presentation
ASX Announcement For personal use only 23 September 2021 InvestorStream Interview - Presentation AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to provide a copy of the presentation by CEO Derek Thomson for the InvestorStream interview. [ASX 17 September 2021Investor Webinar Invi
Slide 2: AnteoTech Ltd Investor Update
For personal use only AnteoTech Ltd (ASX:ADO) Investor Update 23 September 2021 Derek Thomson, CEO 1
Slide 3: Disclaimer
DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these sl
Slide 4: Life Science
For personal use only Life Science 3
Slide 5: EuGeni Leveraging the Platform
EUGENI LEVERAGING THE PLATFORM Our vision is to leverage the EuGeni platform across multiple markets, creating multiple revenue streams. For personal use only Global Distribution Development Network Capability 6 Distributors Strong team of Scientists 13 Territories in pipeline Scientific team growin
Slide 6: EuGeni COVID-19 RAT - Significant Progress in Months
EUGENI – COVID-19 RAT - SIGNIFICANT PROGRESS IN 18 MONTHS For personal use only • Average cost and time for developing and bringing to market a Point of Care Diagnostics Platform is $34M and six years.1 • EuGeni development costs to date a fraction of the industry benchmark. • Development timelines
Slide 7: Reputation & Differentiation Will Drive Success
REPUTATION & DIFFERENTIATION WILL DRIVE SUCCESS For personal use only PERFORMANCE Reader based - Sensitivity 97.3% Specificity 99.6%1 SPEED TO RESULT 15 minutes incubation, less than 1 minute in reader, Up to ~60 tests per hour per reader2 READING WINDOW Valid & consistent result up to 2 hours3 afte
Slide 8: EuGeni Delivers Platform to Scale for Multiple Tests
EUGENI – DELIVERS PLATFORM TO SCALE FOR MULTIPLE TESTS Use the pandemic to gain entry into the global device based PoC Rapid Diagnostic Market through the COVID-19 RAT. For personal use only Leverage the Reader base with Multiple Differentiated Tests.* • Multi market launch of COVID-19 RAT • EuGeni
Slide 9: Growing Global Market Presence
GROWING GLOBAL MARKET PRESENCE Growing European and SE Asian presence, with activities and planning under way for US Market entry in 2022. For personal use only • 7 Distributors signed covering 14 territories Eromediks • 13 additional distributor leads in Apacor varying stages of discussion* Pera •
Slide 10: Manufacturing Strategy - Scaling to Deliver
MANUFACTURING STRATEGY – SCALING TO DELIVER For personal use only • Operon (Spain) existing manufacturing with stock in inventory. • Brisbane (Australia) strip manufacturing to come online early 2022. • Assembly capacity to be added in Australia and Asia Life Science 9 September 2021 1. Assembly par
Slide 11: Sampling Methods That Make the Test More Comfortable
OUR INTENTION IS TO OFFER SAMPLING METHODS THAT MAKE THE TEST MORE COMFORTABLE WITHOUT SACRIFICING PERFORMANCE For personal use only We have chosen not to compromise sensitivity for comfort. Our current sampling development focuses on methods which provide high viral load harvesting sites and comfor
Slide 12: COVID-19 Flu A/B Multiplex
COVID-19 FLU A/B MULTIPLEX The US CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and For personal use only differentiation of SARS-CoV-2 and influenza viruses.1 UV excited EuGeni Multiplex test strip arrangement and detection signal as displaye
Slide 13: Sepsis Family of Tests
SEPSIS FAMILY OF TESTS EuGeni platform for Sepsis - offering de-centralised quantitative diagnostics at Example Interleukin 6 For personal use only Test LoD below Clinical Cut-off Achieved the point of need creating significant values for the platform and AnteoTech. (data on file)1 35 • Accelerated
Slide 14: Energy
For personal use only Energy 13
Slide 15: Our Approach to AnteoX Commercialisation
OUR APPROACH TO ANTEOX COMMERCIALISATION For personal use only ANTEOX • Matching of AnteoX with specific binder Binder material chemistries of collaborators SILICON ANODE manufacturer • Fine-tune AnteoX properties & facilitate Collaborator 8 process integration with collaborators REFERENCE • Progres
Slide 16: Outstanding Results Drive Progression to Customer Demonstrations
OUTSTANDING RESULTS DRIVE PROGRESSION TO CUSTOMER DEMONSTRATIONS For personal use only AnteoX demonstrates a 26% increase in full cell cycle life (at 70% capacity retention)1 • AnteoX anode design capacity set at substantially higher levels compared to current industry standard • AnteoX adds 50 cycl
Slide 17: Progression of Demonstrations
PROGRESSION OF DEMONSTRATIONS For personal use only SILICON ANODE SILICON ANODE REFERENCE REFERENCE DESIGN DESIGN + + Binder material AnteoTech Active material AnteoTech manufacturer manufacturer Collaborator 8 Collaborator 2 Entering Trials Entering Trials Request to Build Full Anode Request to Bui
Slide 18: Appendix
For personal use only Appendix 17
Slide 19: Snapshot Today
SNAPSHOT TODAY For personal use only AnteoTech is commercialising innovative patented technology – with revenue opportunity across two key growth sectors: Point of Care (POC) diagnostics and Lithium-ion battery market • COVID-19 Rapid Antigen Test (RAT) launched April 2021 into growth market $21M1 S
Slide 20: EuGeni COVID-19 RAT - Significant Progress in Months
EUGENI – COVID-19 RAT - SIGNIFICANT PROGRESS IN 18 MONTHS For personal use only The EuGeni COVID-19 RAT rollout is progressing well. Key achievements to date: ✓ Designed, built and delivered first lateral flow test < 12 months on time & budget ✓ Developed EuGeni Reader Platform < 12 months ✓ Achieve
Slide 21: AnteoTech Ltd - Derek Thomson, Chief Executive Officer
For personal use only AnteoTech Ltd (ASX:ADO) Derek Thomson Chief Executive Officer 20